Evotec SE (EVO)
USD 4.33
(-9.41%)
USD 4.33
(-9.41%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 781.42 Million EUR | 3.99% |
| 2022 | 751.44 Million EUR | 21.59% |
| 2021 | 618.03 Million EUR | 23.38% |
| 2020 | 500.92 Million EUR | 12.2% |
| 2019 | 446.43 Million EUR | 18.92% |
| 2018 | 375.4 Million EUR | 45.71% |
| 2017 | 257.63 Million EUR | 56.61% |
| 2016 | 164.5 Million EUR | 28.85% |
| 2015 | 127.67 Million EUR | 42.66% |
| 2014 | 89.49 Million EUR | 4.14% |
| 2013 | 85.93 Million EUR | -1.52% |
| 2012 | 87.26 Million EUR | 8.91% |
| 2011 | 80.12 Million EUR | 45.0% |
| 2010 | 55.26 Million EUR | 29.47% |
| 2009 | 42.68 Million EUR | 7.75% |
| 2008 | 39.61 Million EUR | 20.46% |
| 2007 | 32.88 Million EUR | -51.18% |
| 2006 | 67.35 Million EUR | 5.05% |
| 2005 | 64.11 Million EUR | 3211.02% |
| 2004 | 1.93 Million EUR | -45.81% |
| 2003 | 3.57 Million EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| 2001 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 182.12 Million EUR | -12.75% |
| 2024 Q1 | 208.72 Million EUR | 3.68% |
| 2023 Q1 | 213.55 Million EUR | -11.27% |
| 2023 Q2 | 170.27 Million EUR | -20.26% |
| 2023 Q4 | 201.31 Million EUR | 2.57% |
| 2023 FY | 781.42 Million EUR | 3.99% |
| 2023 Q3 | 196.27 Million EUR | 15.27% |
| 2022 Q3 | 173.88 Million EUR | 0.98% |
| 2022 Q1 | 164.67 Million EUR | -11.97% |
| 2022 Q2 | 172.2 Million EUR | 4.57% |
| 2022 Q4 | 240.68 Million EUR | 38.42% |
| 2022 FY | 751.44 Million EUR | 21.59% |
| 2021 FY | 618.03 Million EUR | 23.38% |
| 2021 Q2 | 138.21 Million EUR | 3.86% |
| 2021 Q1 | 133.08 Million EUR | -5.28% |
| 2021 Q3 | 159.66 Million EUR | 15.51% |
| 2021 Q4 | 187.07 Million EUR | 17.17% |
| 2020 FY | 500.92 Million EUR | 12.2% |
| 2020 Q4 | 140.51 Million EUR | 8.56% |
| 2020 Q3 | 129.42 Million EUR | 15.99% |
| 2020 Q2 | 111.58 Million EUR | -6.55% |
| 2020 Q1 | 119.4 Million EUR | -4.54% |
| 2019 Q1 | 103.84 Million EUR | -1.46% |
| 2019 Q4 | 125.07 Million EUR | 9.45% |
| 2019 Q3 | 114.27 Million EUR | 10.69% |
| 2019 Q2 | 103.23 Million EUR | -0.59% |
| 2019 FY | 446.43 Million EUR | 18.92% |
| 2018 Q2 | 94.77 Million EUR | 19.99% |
| 2018 Q4 | 105.38 Million EUR | 9.48% |
| 2018 FY | 375.4 Million EUR | 45.71% |
| 2018 Q1 | 78.98 Million EUR | -8.98% |
| 2018 Q3 | 96.25 Million EUR | 1.57% |
| 2017 Q3 | 67.45 Million EUR | 26.77% |
| 2017 FY | 257.63 Million EUR | 56.61% |
| 2017 Q4 | 86.77 Million EUR | 28.64% |
| 2017 Q2 | 53.21 Million EUR | 6.03% |
| 2017 Q1 | 50.18 Million EUR | 14.37% |
| 2016 Q2 | 37.97 Million EUR | 1.32% |
| 2016 Q3 | 45.17 Million EUR | 18.95% |
| 2016 Q4 | 43.88 Million EUR | -2.86% |
| 2016 FY | 164.5 Million EUR | 28.85% |
| 2016 Q1 | 37.47 Million EUR | -5.07% |
| 2015 Q2 | 33.41 Million EUR | 55.12% |
| 2015 Q4 | 39.47 Million EUR | 18.77% |
| 2015 FY | 127.67 Million EUR | 42.66% |
| 2015 Q1 | 21.54 Million EUR | -29.52% |
| 2015 Q3 | 33.24 Million EUR | -0.53% |
| 2014 Q2 | 22.47 Million EUR | 27.61% |
| 2014 Q4 | 30.56 Million EUR | 62.16% |
| 2014 FY | 89.49 Million EUR | 4.14% |
| 2014 Q1 | 17.61 Million EUR | -31.26% |
| 2014 Q3 | 18.84 Million EUR | -16.13% |
| 2013 Q3 | 23.63 Million EUR | 20.4% |
| 2013 Q2 | 19.62 Million EUR | 15.01% |
| 2013 Q1 | 17.06 Million EUR | -26.01% |
| 2013 FY | 85.93 Million EUR | -1.52% |
| 2013 Q4 | 25.61 Million EUR | 8.41% |
| 2012 Q1 | 20.11 Million EUR | -1.5% |
| 2012 Q3 | 22.15 Million EUR | 1.0% |
| 2012 Q4 | 23.06 Million EUR | 4.1% |
| 2012 FY | 87.26 Million EUR | 8.91% |
| 2012 Q2 | 21.93 Million EUR | 9.08% |
| 2011 Q3 | 26.34 Million EUR | 44.3% |
| 2011 Q1 | 15.1 Million EUR | -8.01% |
| 2011 Q4 | 20.41 Million EUR | -22.51% |
| 2011 FY | 80.12 Million EUR | 45.0% |
| 2011 Q2 | 18.25 Million EUR | 20.87% |
| 2010 Q3 | 13.87 Million EUR | -8.3% |
| 2010 Q1 | 9.84 Million EUR | -27.36% |
| 2010 FY | 55.26 Million EUR | 29.47% |
| 2010 Q2 | 15.12 Million EUR | 53.71% |
| 2010 Q4 | 16.42 Million EUR | 18.38% |
| 2009 Q2 | 10.5 Million EUR | 27.47% |
| 2009 Q3 | 10.39 Million EUR | -1.0% |
| 2009 Q4 | 13.54 Million EUR | 30.32% |
| 2009 FY | 42.68 Million EUR | 7.75% |
| 2009 Q1 | 8.23 Million EUR | -42.95% |
| 2008 Q4 | 14.44 Million EUR | 35.49% |
| 2008 FY | 39.61 Million EUR | 20.46% |
| 2008 Q3 | 10.65 Million EUR | 47.85% |
| 2008 Q2 | 7.2 Million EUR | -1.43% |
| 2008 Q1 | 7.31 Million EUR | -24.85% |
| 2007 Q4 | 9.73 Million EUR | 31.84% |
| 2007 Q3 | 7.38 Million EUR | -2.38% |
| 2007 Q2 | 7.56 Million EUR | 0.0% |
| 2007 Q1 | - EUR | -100.0% |
| 2007 FY | 32.88 Million EUR | -51.18% |
| 2006 Q3 | 1.69 Million EUR | -40.69% |
| 2006 FY | 67.35 Million EUR | 5.05% |
| 2006 Q4 | 34.05 Million EUR | 1910.04% |
| 2006 Q1 | 2.04 Million EUR | -10.53% |
| 2006 Q2 | 2.85 Million EUR | 39.72% |
| 2005 Q4 | 2.28 Million EUR | 0.0% |
| 2005 Q1 | 506.05 Thousand EUR | 43.37% |
| 2005 Q2 | 541.81 Thousand EUR | 7.06% |
| 2005 Q3 | - EUR | -100.0% |
| 2005 FY | 64.11 Million EUR | 3211.02% |
| 2004 Q2 | 537.81 Thousand EUR | 1.01% |
| 2004 FY | 1.93 Million EUR | -45.81% |
| 2004 Q1 | 532.44 Thousand EUR | 285.4% |
| 2004 Q3 | - EUR | -100.0% |
| 2004 Q4 | 352.97 Thousand EUR | 0.0% |
| 2003 Q1 | - EUR | 0.0% |
| 2003 Q3 | - EUR | 0.0% |
| 2003 Q2 | - EUR | 0.0% |
| 2003 FY | 3.57 Million EUR | 0.0% |
| 2003 Q4 | -287.19 Thousand EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| 2001 FY | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Theratechnologies Inc. | 81.76 Million USD | -855.709% |
| Harrow Health, Inc. | 130.19 Million USD | -500.206% |
| Dynavax Technologies Corporation | 232.28 Million USD | -236.41% |
| Biofrontera Inc. | 34.07 Million USD | -2193.522% |
| Cronos Group Inc. | 88.84 Million USD | -779.579% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -6036.05% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -76.5% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -11897.624% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -1875.667% |
| Radius Health, Inc. | 2.88 Billion USD | 72.888% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -2318.621% |
| DURECT Corporation | 8.54 Million USD | -9041.624% |
| ProPhase Labs, Inc. | 44.38 Million USD | -1660.603% |
| Safety Shot Inc | 202.67 Thousand USD | -385465.698% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 23.215% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -40419.949% |
| Alvotech | 91.43 Million USD | -754.634% |
| Assertio Holdings, Inc. | 152.06 Million USD | -413.863% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -28.625% |
| Rockwell Medical, Inc. | 83.61 Million USD | -834.586% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -3143.402% |
| Procaps Group S.A. | 409.92 Million USD | -90.629% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -68.277% |
| SCYNEXIS, Inc. | 140.14 Million USD | -457.6% |
| Aytu BioPharma, Inc. | 81 Million USD | -864.7% |
| Viatris Inc. | 15.42 Billion USD | 94.935% |
| OptiNose, Inc. | 70.98 Million USD | -1000.802% |
| SIGA Technologies, Inc. | 139.91 Million USD | -458.492% |
| Tilray Brands, Inc. | 788.94 Million USD | 0.953% |
| PetIQ, Inc. | 1.1 Billion USD | 29.088% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -3143.402% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 58.591% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -6279.743% |
| Alimera Sciences, Inc. | 80.75 Million USD | -867.662% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | -37.874% |
| Silver Spike Investment Corp. | 11.72 Million USD | -6566.244% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -80.41% |
| Journey Medical Corporation | 79.18 Million USD | -886.886% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -13321.057% |
| Alpha Teknova, Inc. | 36.68 Million USD | -2030.155% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -4386.571% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -509.247% |
| PainReform Ltd. | - USD | -Infinity% |
| Cosmos Health Inc. | 53.37 Million USD | -1363.979% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -2694.5% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -59917.358% |
| Embecta Corp. | 1.12 Billion USD | 30.28% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Talphera, Inc. | 651 Thousand USD | -119934.716% |
| Pacira BioSciences, Inc. | 674.97 Million USD | -15.771% |
| Incannex Healthcare Limited | 12 Thousand USD | -6511783.333% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -72495.91% |
| Shineco, Inc. | 9.8 Million USD | -7872.225% |
| Procaps Group, S.A. | 409.92 Million USD | -90.629% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | -60.518% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -1444.839% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 39.725% |
| Alvotech | 91.43 Million USD | -754.634% |
| Hempacco Co., Inc. | 4.04 Million USD | -19215.277% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | -146.81% |
| Bright Green Corporation | 401.49 Thousand USD | -194531.013% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -571.709% |
| Kamada Ltd. | 144.75 Million USD | -439.812% |
| Indivior PLC | 1.09 Billion USD | 28.506% |
| Evoke Pharma, Inc. | 5.18 Million USD | -14983.61% |
| Flora Growth Corp. | 76.07 Million USD | -927.232% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -72495.91% |
| Evolus, Inc. | 202.08 Million USD | -286.682% |
| HUTCHMED (China) Limited | 837.99 Million USD | 6.751% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | -21.265% |
| Akanda Corp. | 2.16 Million USD | -36076.259% |